We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 27, 2021

This is the Future of Digital Therapeutics

Reports
HealthXL Research Team
&
Brian Dolan

Sneak peek into our upcoming report

We are excited to give you a sneak peek into our upcoming report on Prescription Digital Therapeutics. 

In 2018, we released our first report on Digital Therapeutics (DTx), aiming to get behind the hype and dig into the DTx landscape, business models, regulation, reimbursement, evidence, and adoption. In the past two years, a lot has happened. A wide variety of companies have co-opted the term “digital therapeutics” to describe their digital health offerings. This report seeks to cut through some of that noise by focusing on a smaller subset of this group: prescription digital therapeutics (PDT).

We are excited to announce that for our 2021 PDT report, we are collaborating with Brian Dolan of Exits & Outcomes (E&O). E&O is a digital health research and media company led by Brian, who also founded MobiHealthNews back in 2008. 

The objective of this HealthXL- E&O Report is to deep dive into one subsegment of DTx that has enormous potential: prescription products. We shine a light on clinical validation, adoption, investments, reimbursement and regulation. 

This report contains key examples of PDT applications, industry implications and a critical viewpoint of the current reality of the DTx environment and those which must be addressed in order to truly deliver on the DTx promise in terms of optimized health outcomes. 

What can you expect to see? 


Investment / Solutions Landscape

We examine how the investment landscape for PDTs has changed over 2018-2020.  It is clear that COVID-19 has hugely increased investments/partnerships within the digital health space, PDTs included! The top funded PDT company of 2020 was Biofourmis, obtaining a whopping $100 million in investments.

Source: Portal.HealthXL.com


Business Models and Pricing

Business models and pricing for digital therapeutics are some of the most sought after details among large corporations, investors and startups alike. In this section of the report we outline different PDT business models which include those that follow the more traditional pharmaceutical pathways to sell their products, and newly emerging models which are leveraging telemedicine to facilitate D2C access. We also take a look at the pricing of PDTs which are currently available on the market.

Clinical and Economic Outcomes

Only 27% of PDTs have published RCTs to validate their product offerings. We compare and contrast the current frameworks that support the validation of PDTs [NICE, FDA, TGA, DIGA], and dig into the rigor of evidence provided for these products vs traditional pharmaceutical agents. We also discuss the use of digital endpoints (or lack thereof) in the validation of these products.

Regulatory Environment, Reimbursement and Prescription Pathways


The report digs deep into the regulatory environment and prescription pathways for PDTs in both the US and the EU. We also assess the reimbursement landscape for PDTs across the globe - while developments in the US remain thin, the EU and Japan appear to be leading the charge in the reimbursement space. 

Source: Portal.HealthXL.com


Adoption and Enablement

Prescription capabilities remain a key challenge in the adoption of PDTs, although Germany and Belgium are spearheading change within this space. In the report we take a deep dive into the adoption and enablement of PDTs, fleshing out regional differences and highlighting companies that are shaking up the distribution chain.


The Future of PDT

PDTs are quickly emerging as one of the most spoken about areas of digital health, although it would appear that many barriers remain for the widespread adoption of these technologies. What needs to happen in politics, within the FDA, within PBMs, in the minds of physicians and consumers to move the needle? We gaze into the crystal ball.


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to Navigate the NHS Digital Technology Assessment Criteria and NICE evidence guidelines

1st February @ 10AM GMT / 6PM AWST

Are you trying to increase adoption and use of your Digital Health solution across the UK's National Health Service? Join your peers in this meeting as they deep dive into this topic. Apply now to secure your place as seats are limited.

Featuring
Richard Bunney
Richard Bunney
Director, Cuniculo Ltd
Featuring
Richard Bunney
Richard Bunney
Director, Cuniculo Ltd
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health in Oncology
31st January @ 10:45AM EDT

Are Hospitals the Right Partner for Digital Health Companies in Oncology?

Digital health in oncology is still a very raw and undefined practice with companies still searching for a best approach to put these solutions into the patients' hands. Join this peer-to-peer conversation to deep dive into this discussion.

Eoin Tabb
Featuring
Eoin Tabb
A/ Chief II Pharmacist, Cancer Services, HSE
Clinical Trials Innovation
1st February @ 11AM EDT

HealthXL Webinar: The Potential of AI in Drug Discovery

The drug discovery process has traditionally been costly and very time-consuming. Join this Webinar to deep dive into this topic with senior leaders in this area.

Armen Vidian
Featuring
Armen Vidian
Digital Health Venture Capitalist
Digital Therapeutics (DTx)
1st February @ 10AM GMT / 6PM AWST

Masterclass: How to Navigate the NHS Digital Technology Assessment Criteria and NICE evidence guidelines

Are you trying to increase adoption and use of your Digital Health solution across the UK's National Health Service? Join your peers in this meeting as they deep dive into this topic. Apply now to secure your place as seats are limited.

Richard Bunney
Featuring
Richard Bunney
Director, Cuniculo Ltd
Telemedicine & Virtual Care Delivery
2nd February @ 10:45AM EDT

Masterclass: How to Make Value-Based Health Care (VBHC) work with Digital Health?

Would you like to learn more about value-based health care models (VBHC) and the interplay between these systems and digital health solutions? Join HealthXL in this Masterclass led by Matt Hickey to deep dive into this topic. Seats are limited so apply now to secure your place.

Matt Hickey
Featuring
Matt Hickey
CEO, The Health Value Alliance

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.